Home Oncology Oncology News NCCN recommends a third COVID-19 dose for patients with cancer

NCCN recommends a third COVID-19 dose for patients with cancer


Experts on the National Comprehensive Cancer Network (NCCN) have now issued updated recommendations for COVID-19 vaccination in individuals with cancer. The panel calls for those patients to be among the many highest precedence group to be vaccinated in opposition to COVID-19 and to obtain the newly accredited third dose of vaccine.

The NCCN has recommended in February that all patients receiving active cancer treatment ought to obtain a COVID-19 vaccine and must be prioritized for vaccination. Two weeks ago, the FDA licensed the 3rd dose of both the Pfizer or Moderna COVID-19 vaccines for individuals with compromised immune programs. Those eligible for a 3rd dose embody strong organ transplant recipients, those present process cancer therapies, and other people with autoimmune diseases that suppress their immune systems.


Wearable activity monitors after breast cancer treatment help patients and their doctors monitor recovery

The new NCCN recommendations state that the following groups must be thought-about eligible for a 3rd dose of the mRNA COVID-19 vaccine instantly, based mostly on the newest decisions from the Food and Drug Administration and the Centers for Disease Control and Prevention:

– Patients with strong tumors (both new or recurring) receiving treatment within 1 year of their preliminary vaccine dose, no matter their kind of cancer therapy.

– Patients with active hematologic malignancies no matter whether or not they’re at the moment receiving cancer therapy.

– Anyone who obtained a stem cell transplant (SCT) or engineered mobile therapy (e.g. CAR T-cells), particularly within the past 2 years.

– Any recipients of allogeneic SCT on immunosuppressive therapy or with a history of graft-versus-host disease regardless of the time of transplant.

– Anyone with an extra immunosuppressive situation (eg, HIV) or being handled with immunosuppressive brokers unrelated to their cancer therapy.

Cancer Patients at High Risk of Complications

As previously reported by Medscape Medical News, an infection with COVID-19 in individuals with cancer can severely impact survival. One research printed last year discovered that patients with both COVID-19 infection and progressing cancer had a fivefold improvement within the threat of 30-day mortality, in contrast with COVID-19–positive cancer patients who had been in remission or had no evidence of cancer.

Another study found that cancer kind, stage, and recent treatment may have an effect on outcomes of COVID-19 in patients with cancer. Patients with hematologic malignancies and metastatic cancers had higher risks of creating severe or important COVID-19 signs, being admitted to the intensive care unit, requiring airflow, and dying. Conversely, those with the nonmetastatic disease had outcomes that had been comparable with individuals without cancer and a COVID-19 infection. This research additionally discovered that having undergone the latest surgery or receiving immunotherapy additionally put patients at the next threat of poor outcomes, though patients with cancer who had been handled with radiotherapy had outcomes just like these of noncancer COVID-19 patients.

“COVID-19 could be very harmful, particularly for individuals residing with cancer, which is why we’re so grateful for safe and efficient vaccines which might be saving lives,” said Robert W. Carlson, MD, chief govt officer of NCCN, in a press release.

Proper Timing and Location

The present NCCN update additionally recommends that people wait at least 4 weeks between the second and third doses while people who are contaminated with COVID-19 after being vaccinated ought to wait till they’ve documented clearance of the virus earlier than receiving the third dose.

It additionally recommends that individuals who live in the same family with immunocompromised people also need to get a 3rd dose as soon as it turns accessible and that it’s best to have a 3rd dose of the identical kind of vaccine as the first two doses. Nevertheless, a special mRNA vaccine can be acceptable.

Immunocompromised people ought to attempt to obtain their third dose in a healthcare supply setting, versus a pharmacy or public vaccination clinic if doable, as it could restrict their risk of publicity to the general population.

Steve Pergam, MD, MPH, affiliate professor, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, commented that it’s nonetheless essential to take precautions, even after getting the booster dose.

“Meaning even after the 3rd dose of vaccine, we nonetheless recommend immunocompromised individuals, akin to these present process cancer treatment, proceed to be cautious, put on masks, and keep away from massive group gatherings, significantly round those that are unvaccinated,” said Pergam, who can be co-leader of the NCCN COVID-19 Vaccination Advisory Committee. “All of us ought to do our part to reduce the spread of COVID-19 and get vaccinated to protect these around us from preventable struggling.”




Please enter your comment!
Please enter your name here

Exit mobile version